Gonadorelin
Also known as: GnRH, LHRH, Factrel, Lutrepulse, Gonadotropin-Releasing Hormone
Overview
Clinical Summary
Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). It is FDA-approved under the brand name Factrel for diagnostic evaluation of pituitary gonadotroph function and was previously available as Lutrepulse for pulsatile GnRH therapy in hypothalamic amenorrhea. In current clinical practice, gonadorelin is widely used off-label in men's health clinics to maintain pituitary LH and FSH secretion during testosterone replacement therapy (TRT), thereby preserving testicular function and spermatogenesis. Pulsatile GnRH administration has demonstrated fertility restoration in both men and women with hypothalamic hypogonadism.
Plain Language Summary
Gonadorelin is a synthetic version of the natural hormone (GnRH) that tells your pituitary gland to produce LH and FSH, which in turn stimulate testosterone production and sperm development. It is FDA-approved for testing pituitary function. Many men's health clinics use it alongside testosterone therapy to keep the testes active and maintain fertility. It can also be used to restore fertility in people with certain hormonal conditions.
Mechanism of Action
Gonadorelin binds to the GnRH receptor (GnRH-R) on pituitary gonadotroph cells, stimulating the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The physiological response depends on the pattern of administration: pulsatile delivery (every 60 to 120 minutes) mimics the natural hypothalamic GnRH pulse generator and maintains normal gonadotroph function, while continuous administration causes receptor desensitization and paradoxical suppression of LH and FSH (the basis for GnRH agonist suppression in prostate cancer and IVF). In the TRT co-administration context, subcutaneous gonadorelin injections aim to maintain sufficient LH pulsatility to preserve intratesticular testosterone and spermatogenesis.
Evidence Summary
Gonadorelin has extensive clinical evidence as a diagnostic and therapeutic agent. Martin et al. (1990) demonstrated that pulsatile GnRH therapy restored gonadotropin pulsatility and gonadal function in hypothalamic hypogonadism, inducing ovulation in women and spermatogenesis in men. The FDA-approved diagnostic use (Factrel label) is supported by studies showing reliable LH/FSH stimulation for evaluating pituitary reserve. Off-label use in TRT co-administration is supported by retrospective and review data (Lee and Ramasamy, 2018) showing maintenance of spermatogenesis parameters, though large RCTs for this specific indication are lacking.
Safety Profile
Gonadorelin has an excellent safety profile established over decades of clinical use. Adverse events are uncommon and generally mild. The most frequently reported effects include headache, flushing, nausea, and injection site reactions. Allergic reactions (including anaphylaxis) are rare but documented. Multi-dose use has not revealed cumulative toxicity. The primary clinical risk is related to the desired pharmacological effect rather than drug toxicity.
Contraindications
- Known hypersensitivity to GnRH or any component
- Conditions that could be worsened by gonadotropin release (hormone-sensitive tumors)
- Pregnancy (may stimulate uterine contractions in late pregnancy)
- Pituitary apoplexy (avoid stimulation in acute setting)
Adverse Events
- Headache
- Flushing
- Nausea
- Injection site reactions (pain, swelling)
- Abdominal discomfort
- Lightheadedness
- Allergic reactions (rare)
- Anaphylaxis (very rare)
Interactions
- Androgens and estrogens may blunt the LH/FSH response
- Dopamine antagonists may enhance gonadotropin release
- GnRH analogues (leuprolide, goserelin) will interfere with pituitary response assessment
- Oral contraceptives suppress the HPG axis and blunt response
Regulatory Notes
Gonadorelin is FDA-approved (Factrel) for diagnostic evaluation of gonadotroph function. Lutrepulse (pulsatile GnRH pump) was previously FDA-approved but is no longer commercially available. Off-label use in TRT co-administration is widespread in men's health clinics. Compounding pharmacies prepare gonadorelin for subcutaneous injection. Generic versions are available.
Monitoring Considerations
For diagnostic use: serial LH and FSH sampling at 15, 30, 45, 60, and 120 minutes after injection. For TRT co-administration: periodic LH, FSH, total testosterone, and semen analysis. Estradiol levels should be monitored. In fertility applications: ultrasound monitoring of follicular development (women) or semen analysis (men).
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Pharmaceutical-grade gonadorelin: store lyophilized at room temperature (20 to 25 degrees C). After reconstitution with supplied diluent, use immediately for diagnostic testing. For multi-dose subcutaneous use (compounded), store reconstituted solution at 2 to 8 degrees C and use within 14 to 28 days per compounder specifications. Protect from light.
References
- 1FDA label
FACTREL (Gonadorelin Hydrochloride) Prescribing Information
Ayerst Laboratories (1986). FDA
Key findings: FDA-approved diagnostic agent for evaluating pituitary gonadotroph function. Synthetic decapeptide identical to endogenous GnRH. Single IV or SC dose followed by serial LH/FSH sampling.
Limitations: Diagnostic use label only. Does not cover therapeutic fertility applications.
- 2RCT
Pulsatile GnRH Therapy for Hypothalamic Amenorrhea and Male Hypogonadotropic Hypogonadism
Martin K, Santoro N, Hall J, et al. (1990). Journal of Clinical Endocrinology & Metabolism
Key findings: Pulsatile GnRH administration restored physiological gonadotropin pulsatility and gonadal function in patients with hypothalamic hypogonadism. Ovulation induction in women and spermatogenesis in men were achieved.
Limitations: Requires pulsatile pump delivery. Not practical for widespread outpatient use. Small studies.
- 3review
Concomitant Use of Gonadorelin to Maintain Fertility During Testosterone Replacement Therapy
Lee JA, Ramasamy R. (2018). Translational Andrology and Urology
Key findings: Review of strategies to preserve spermatogenesis in men on TRT. Gonadorelin and GnRH pulsatile therapy maintain LH/FSH secretion and support intratesticular testosterone levels needed for spermatogenesis.
Limitations: Narrative review. Off-label use. Limited controlled trial data for TRT co-administration specifically.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Sexual Health
PT-141 (Bremelanotide)
Bremelanotide · Vyleesi · PT-141
Bremelanotide (brand name Vyleesi) is an FDA-approved medication for low sexual desire in premenopausal women. It works on receptors in the brain that are involved in sexual arousal and desire. It is given as a self-injection before anticipated sexual activity. It was originally discovered during research into tanning peptides (melanotan) when researchers noticed it increased sexual arousal as a side effect.
Kisspeptin
Kisspeptin-54 · Kisspeptin-10 · Metastin · KISS1
Kisspeptin is a natural hormone that acts as the 'master switch' for your reproductive system. It tells your brain to start the hormone cascade that leads to testosterone or estrogen production. Researchers are studying synthetic kisspeptin for fertility treatments and for boosting sexual desire. Early results are promising, especially for triggering egg maturation in IVF with less risk of a dangerous side effect called ovarian hyperstimulation. It is still investigational.
Melanotan II
MT-II · MT-2 · Melanotan 2
Melanotan II is a peptide that causes skin tanning without UV exposure and also increases sexual arousal. It works by activating melanocortin receptors throughout the body. While it is popular in the grey market for tanning and sexual enhancement, it has serious safety concerns. Common side effects include severe nausea and changes in blood pressure. More concerning, it can cause moles to darken or change, raising worries about melanoma risk. It is not approved for any use and a safer derivative (bremelanotide/Vyleesi) was developed for sexual dysfunction instead.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider